Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMRIX vs AMITRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Hepatic, primarily via CYP2D6 and CYP3A4, with contributions from CYP1A2 and CYP2C19. Amitriptyline is metabolized to nortriptyline (active) and other metabolites.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
40–45% bound to serum proteins, primarily albumin
90–95% bound to albumin and alpha-1-acid glycoprotein.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Vd: 15–30 L/kg; extensive tissue distribution, including CNS.
Oral: 85–95% (extended-release formulation)
Oral: 30–60% due to first-pass metabolism.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
GFR 30-59 m L/min: Reduce dose by 50%. GFR 15-29 m L/min: Reduce dose by 75%. GFR <15 m L/min: Contraindicated. Hemodialysis: Not dialyzable; avoid use.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use contraindicated or reduce dose by 75% with extreme caution.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Children ≥12 years: Initial 25-50 mg/day PO, increase gradually to 100 mg/day in divided doses. Children 6-11 years: 1-3 mg/kg/day PO in divided doses, not to exceed 100 mg/day. Not recommended under 6 years.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Initial 10-25 mg PO at bedtime, with gradual titration. Maintenance often 50-100 mg/day. Monitor for orthostatic hypotension, falls, and anticholinergic effects.
None
Amitriptyline is not approved for use in pediatric patients. Clinical worsening and suicide risk: Monitor for clinical worsening, suicidality, or unusual changes in behavior during initial therapy. Serotonin syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Suicidality in children, adolescents, and young adults; serotonin syndrome; activation of mania/hypomania; seizures; angle-closure glaucoma; urinary retention; cardiovascular effects (QT prolongation, arrhythmias); impaired cognitive/motor performance.
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Hypersensitivity to amitriptyline or any component; concomitant use with MAOIs or within 14 days of MAOI use; recent myocardial infarction; during acute recovery phase after MI; concomitant use with cisapride.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
Avoid grapefruit and grapefruit juice as they may increase serum levels of amitriptyline. Limit tyramine-rich foods (aged cheeses, cured meats, fermented products) if taking MAOIs concurrently (contraindicated). Alcohol consumption may enhance sedative effects and is not recommended. High-fat meals may delay absorption but do not significantly alter overall exposure.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and direct toxic effects (tachycardia, urinary retention). Late third trimester: Possible persistent pulmonary hypertension of the newborn (PPHN) with SSRI-like effects, though data limited for tricyclics.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
M/P ratio approximately 1.0-1.5. Excreted in breast milk in low amounts. Infant serum levels are usually subtherapeutic but cases of drowsiness, irritability reported. Use with caution; monitor infant for sedation and feeding difficulties. American Academy of Pediatrics considers compatible with breastfeeding if infant is healthy and full-term.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, lower serum concentrations may occur. Monitor clinical response; dose adjustments may be needed but no standard guidelines. Use lowest effective dose. Taper if discontinuing to avoid withdrawal.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
For neuropathic pain, start at 10-25 mg at bedtime; titrate slowly to reduce sedative effects. Monitor QTc interval at baseline and with dose increases, especially in patients with cardiac risk factors. Anticholinergic effects (dry mouth, constipation) are common; consider prophylactic stool softeners. Avoid abrupt discontinuation; taper over 2-4 weeks to prevent withdrawal symptoms.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
Take exactly as prescribed, usually once daily at bedtime due to drowsiness.,Do not stop suddenly; taper under doctor's guidance to avoid nausea, headache, or insomnia.,Avoid alcohol and other CNS depressants (e.g., sedatives, opioids) as they increase sedation risk.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) or cardiac symptoms (e.g., palpitations, fainting).,May cause dry mouth, constipation, blurred vision; use sugar-free gum, hydrate, and consider fiber supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMRIX vs AMITRIL, answered by our medical review team.
AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. AMITRIL is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMRIX and AMITRIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. The standard adult dose of AMITRIL is: Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMRIX and AMITRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. AMITRIL is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.